Literature DB >> 14648333

Non-glucocorticoid-remediable aldosteronism in an infant with low-renin hypertension.

Maricarmen Malagon-Rogers1.   

Abstract

A 6-week-old male with severe hypertension is presented. He was found to have hyperaldosteronism and a negative long polymerase chain reaction (PCR) test for glucocorticoid-remediable aldosteronism. His mother and maternal grandfather also had severe hypertension. A case is made for the possible diagnosis of familial hyperaldosteronism type II at a very early age.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14648333     DOI： 10.1007/s00467-003-1339-2

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN： 0931-041X            Impact factor:   3.714


  10 in total

1.  Glucocorticoid-remediable aldosteronism is associated with severe hypertension in early childhood.

Authors:  R G Dluhy; B Anderson; B Harlin; J Ingelfinger; R Lifton
Journal:  J Pediatr       Date:  2001-05       Impact factor: 4.406

2.  Familial forms broaden the horizons for primary aldosteronism.

Authors:  R D Gordon; M Stowasser
Journal:  Trends Endocrinol Metab       Date:  1998-08       Impact factor: 12.015

Review 3.  Familial varieties of primary aldosteronism.

Authors:  M Stowasser; T G Gunasekera; R D Gordon
Journal:  Clin Exp Pharmacol Physiol       Date:  2001-12       Impact factor: 2.557

Review 4.  Neonatal hypertension: diagnosis and management.

Authors:  J T Flynn
Journal:  Pediatr Nephrol       Date:  2000-04       Impact factor: 3.714

Review 5.  Familial hyperaldosteronism.

Authors:  M Stowasser; R D Gordon
Journal:  J Steroid Biochem Mol Biol       Date:  2001-09       Impact factor: 4.292

6.  A novel genetic locus for low renin hypertension: familial hyperaldosteronism type II maps to chromosome 7 (7p22).

Authors:  A R Lafferty; D J Torpy; M Stowasser; S E Taymans; J P Lin; P Huggard; R D Gordon; C A Stratakis
Journal:  J Med Genet       Date:  2000-11       Impact factor: 6.318

Review 7.  Inherited forms of mineralocorticoid hypertension.

Authors:  P C White
Journal:  Hypertension       Date:  1996-12       Impact factor: 10.190

8.  Familial hyperaldosteronism type II: five families with a new variety of primary aldosteronism.

Authors:  M Stowasser; R D Gordon; T J Tunny; S A Klemm; W L Finn; A L Krek
Journal:  Clin Exp Pharmacol Physiol       Date:  1992-05       Impact factor: 2.557

9.  Evaluation of the dexamethasone suppression test for the diagnosis of glucocorticoid-remediable aldosteronism.

Authors:  W R Litchfield; M I New; C Coolidge; R P Lifton; R G Dluhy
Journal:  J Clin Endocrinol Metab       Date:  1997-11       Impact factor: 5.958

10.  A new genetic test for familial hyperaldosteronism type I aids in the detection of curable hypertension.

Authors:  J R Jonsson; S A Klemm; T J Tunny; M Stowasser; R D Gordon
Journal:  Biochem Biophys Res Commun       Date:  1995-02-15       Impact factor: 3.575
  10 in total
  4 in total

Review 1.  Hypertension in infancy: diagnosis, management and outcome.

Authors:  Janis M Dionne; Carolyn L Abitbol; Joseph T Flynn
Journal:  Pediatr Nephrol       Date:  2011-01-22       Impact factor: 3.714

2.  A novel form of human mendelian hypertension featuring nonglucocorticoid-remediable aldosteronism.

Authors:  David S Geller; Junhui Zhang; Max V Wisgerhof; Cedric Shackleton; Michael Kashgarian; Richard P Lifton
Journal:  J Clin Endocrinol Metab       Date:  2008-05-27       Impact factor: 5.958

3.  Characteristics of hypertension in premature infants with and without chronic lung disease: a long-term multi-center study.

Authors:  Randall D Jenkins; Julia K Aziz; Ladawna L Gievers; Harrison M Mooers; Nora Fino; David J Rozansky
Journal:  Pediatr Nephrol       Date:  2017-07-03       Impact factor: 3.714

4.  GRAde: a long-read sequencing approach to efficiently identifying the CYP11B1/CYP11B2 chimeric form in patients with glucocorticoid-remediable aldosteronism.

Authors:  Yu-Ching Wu; Chia-I Chen; Peng-Ying Chen; Chun-Hung Kuo; Yi-Hsuan Hung; Kang-Yung Peng; Vin-Cent Wu; Jyy-Jih Tsai-Wu; Chia-Lang Hsu
Journal:  BMC Bioinformatics       Date:  2022-01-10       Impact factor: 3.169
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.